ResMed's total inventories for the quarter that ended in Mar. 2026 was €789 Mil. ResMed's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €788 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. ResMed's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €3.42.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
ResMed's Days Inventory for the
three
months ended in Mar. 2026 was 153.84.
Inventory Turnover measures how fast the company turns over its inventory within a year.
ResMed's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.59.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ResMed's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.64.
ResMed (WBO:RMD) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
ResMed's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ResMed's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
ResMed Total Inventories Related Terms
ResMed Total Inventories Historical Data
* Premium members only.
The historical data trend for ResMed's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
ResMed (WBO:RMD) has a Total Inventories of €789 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for ResMed and its competitors.
Is ResMed's Total Inventories too high?
ResMed's current Total Inventories is €789 Mil. Overall, ResMed has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Total Inventories compare to MDLN and WST?
ResMed's Total Inventories of €789 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for ResMed and its competitors. ResMed's current Total Inventories is €789 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (WBO:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is €239.75, compared to a current price of €172.75 — trading 27.9% below its estimated fair value. The current Total Inventories is €789 Mil. ResMed's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For ResMed (WBO:RMD), the current Total Inventories is €789 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (WBO:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of €172.75 is trading 27.9% below its estimated GF Value™ of €239.75.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for WBO:RMD:
Total Inventories: €789 Mil
GF Value™: €239.75 vs. price of €172.75 (27.9% below fair value)
No single metric tells the full story. See the WBO:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
92GF Score
Get the complete analysis for WBO:RMD
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:RMD has been successfully added to your 
